Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | AKT1 | P31749 | 3/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23576881 | 1.00 | ACHE (0.34) | ACHEAKT1GRK6LMNAHPGD | |
| SCHEMBL24813187 | 0.90 | AKT1 (0.34) | AKT1LRRK2 | |
| SCHEMBL24815926 | 0.87 | ACHE (0.33) | ACHEGRK6LMNAHPGDMAPK1 | |
| SCHEMBL24813174 | 0.87 | ACHE (0.41) | ACHEKDM4E | |
| SCHEMBL29909500 | 0.86 | ACHE (0.43) | ACHEKDM4E | |
| SCHEMBL29909192 | 0.85 | ABL1 (0.35) | ACHEAKT1TSHRABL1BCR | |
| SCHEMBL23577305 | 0.85 | ABL1 (0.35) | ACHEAKT1TSHRABL1BCR | |
| SCHEMBL24816017 | 0.83 | MAPK1 (0.36) | ACHELMNAHPGDMAPK1KDM4E | |
| SCHEMBL29162213 | 0.77 | AKT1 (0.32) | AKT1ABL1BCR | |
| SCHEMBL24813570 | 0.77 | ACHE (0.33) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| EP-4359415-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | ACHE 4227/4885AKT1 45/4885GRK6 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.